S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
Laser breakthrough could send stock soaring 2,467% (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
Laser breakthrough could send stock soaring 2,467% (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
Laser breakthrough could send stock soaring 2,467% (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Laser breakthrough could send stock soaring 2,467% (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks That Flourish In The Fall
2 Must-Have Silicon Companies That Don't Make Microchips
Laser breakthrough could send stock soaring 2,467% (Ad)
Buy The World’s Largest IT Infrastructure Provider For Under $20
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:NVAX

Novavax (NVAX) Stock Forecast, Price & News

$7.31
+0.18 (+2.52%)
(As of 09/25/2023 ET)
Compare
Today's Range
$6.90
$7.57
50-Day Range
$6.81
$9.74
52-Week Range
$5.61
$25.66
Volume
8.34 million shs
Average Volume
7.26 million shs
Market Capitalization
$690.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

Novavax MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
378.8% Upside
$35.00 Price Target
Short Interest
Bearish
42.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
0.21mentions of Novavax in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.83) to ($0.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

512th out of 962 stocks

Biological Products, Except Diagnostic Industry

80th out of 160 stocks


NVAX stock logo

About Novavax (NASDAQ:NVAX) Stock

Novavax Inc is a biotechnology company that focuses on developing vaccines and biological therapies that combat infectious diseases. The company is headquartered in Gaithersburg, Maryland and has several locations across the United States and Europe. Novavax has a strong track record of developing novel vaccine candidates and has achieved significant milestones in recent years.

In 2020 the company redirected all efforts into finding a vaccine for the COVID-19 pandemic releasing its NVX-CoV2373 vaccine called Nuvaxovid, which has been approved for use in the European Union and Canada. 

Novavax Inc's team is led by CEO John C. Jacobs, who was appointed CEO and board member in Q1 of 2023. Mr. Jacobs has over 25 years of commercial and business operation skills and has demonstrated leadership across multiple therapeutic areas. Mr. Jacobs previously served as CEO and board member at Harmony Biosciences, where he served for five years, leading that company through a successful initial public offering (IPO).

Other notable team members include Dr. Gregory Glenn, the President of Research and Development, with 28 years of vaccine design and regulatory experience. Also noteworthy is Dr. Filip Dubovsky, Novavax Inc's Executive Vice President and Chief Medical Officer, a recognized leader in vaccine development and who joined the company after a 15-year tenure at AstraZeneca, another leading vaccine manufacturer. 

Over the past few years, Novavax has reported steady revenue growth. The company's revenue has increased year over year, reporting net income up each year since 2021. The company's debt levels are high, with total liabilities exceeding total assets for multiple years. Novavax's valuation metrics are in line with industry peers. The company's price-to-earnings ratio and the company's price-to-book ratio are in line with industry peers.

These metrics suggest that the market is valuing Novavax appropriately. Novavax's stock performance has been volatile in recent years. The company's stock price increased significantly in 2020 due to its COVID-19 vaccine development efforts. However, the stock price has since declined, as Novavax has faced delays in obtaining regulatory approvals for its COVID-19 vaccine. Despite these setbacks, the company's long-term prospects remain strong.

The vaccine industry is highly competitive and has significant regulatory and political risks. Novavax faces competition from established pharmaceutical companies, as well as other biotechnology companies that are developing vaccines. However, the company's focus on innovative vaccine candidates, such as its COVID-19 vaccine, gives it a competitive advantage. The vaccine industry is also subject to regulatory risks, as government policy changes can significantly impact the market. Novavax's strong relationships with regulatory agencies give it an advantage in navigating this challenging environment.

Novavax has several growth opportunities in the near term. The company's COVID-19 vaccine has shown promising results in clinical trials and has received regulatory approval in multiple markets. Novavax also has several other vaccine candidates in development, including respiratory syncytial virus (RSV) and influenza vaccines. The company's pipeline of innovative vaccine candidates positions it for long-term growth and success.

Novavax faces several risks and challenges that could impact its long-term success. The company's vaccine candidates are subject to regulatory approval, which can be lengthy and expensive. Novavax also faces significant competition from established pharmaceutical companies and other biotechnology companies. Changes in consumer preferences or shifts in government policies could also impact the market for Novavax's products. 

NVAX Price History

NVAX Stock News Headlines

2 Stocks That Doubled EPS Estimates and Flashing Buy Signals (NVAX)
The second quarter of the 2023 earnings season has drawn to a close. There were many surprises in every sector. However, there were some standout surprises with
Updated COVID boosters to divide America
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Europe to decide on Novavax's COVID vaccine in October
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Up 20% in 1 Month, Is This Stock a Buy?
Novavax Stock (NASDAQ:NVAX) Has a Shot at Recovering
Novavax recovers as Pfizer and Moderna lead on Covid booster
US CDC contemplates who should get the new COVID shots
US FDA authorizes updated COVID vaccines
Novavax Unusual Options Activity For September 08
Novavax: Sell A Covid Bounce
See More Headlines
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,992
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$35.00
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+378.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-657,940,000.00
Pretax Margin
-36.65%

Debt

Sales & Book Value

Annual Sales
$1.98 billion
Book Value
($8.08) per share

Miscellaneous

Free Float
93,554,000
Market Cap
$690.06 million
Optionable
Optionable
Beta
1.69

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. James Patrick Kelly C.F.A. (Age 57)
    Exec. VP, CFO & Treasurer
    Comp: $644.32k
  • Mr. John A. Herrmann IIIMr. John A. Herrmann III (Age 57)
    J.D., Exec. VP & Chief Legal Officer
    Comp: $658.3k
  • Mr. Stanley Charles Erck (Age 75)
    Advisor
    Comp: $1.09M
  • Mr. John Joseph Trizzino B.S. (Age 63)
    M.B.A., Exec. VP, Chief Commercial Officer & Chief Bus. Officer
    Comp: $641.22k
  • Mr. John Charles Jacobs M.B.A. (Age 56)
    Pres, CEO & Director
  • Mr. Richard P. Crowley (Age 66)
    Exec. VP & COO
  • Mr. Troy Morgan Esq. (Age 52)
    J.D., Sr. VP & Chief Compliance Officer
  • Ms. Erika S. Trahan
    Associate Director of Investor & PR
  • Mr. Ian J. Watkins (Age 60)
    Exec. VP & Chief HR Officer
  • Ms. Silvia Taylor M.B.A.
    MBA, Exec. VP and Chief Corp. Affairs & Advocacy Officer













NVAX Stock - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVAX shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price forecast for 2023?

4 analysts have issued 1 year price targets for Novavax's stock. Their NVAX share price forecasts range from $15.00 to $55.00. On average, they predict the company's share price to reach $35.00 in the next year. This suggests a possible upside of 378.8% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How have NVAX shares performed in 2023?

Novavax's stock was trading at $10.28 at the start of the year. Since then, NVAX shares have decreased by 28.9% and is now trading at $7.31.
View the best growth stocks for 2023 here
.

When is Novavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NVAX earnings forecast
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) issued its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.58 EPS for the quarter, beating the consensus estimate of ($1.24) by $1.82. The biopharmaceutical company earned $424.40 million during the quarter, compared to the consensus estimate of $264.16 million. The business's quarterly revenue was up 128.3% on a year-over-year basis. During the same period in the previous year, the business posted ($6.53) EPS.

When did Novavax's stock split?

Novavax's stock reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.50 billion, compared to the consensus revenue estimate of $1.44 billion.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (12.37%), BlackRock Inc. (7.41%), Shah Capital Management (6.35%), Geode Capital Management LLC (1.85%), Citigroup Inc. (0.00%) and Northern Trust Corp (0.92%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends
.

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $7.31.

How much money does Novavax make?

Novavax (NASDAQ:NVAX) has a market capitalization of $690.06 million and generates $1.98 billion in revenue each year. The biopharmaceutical company earns $-657,940,000.00 in net income (profit) each year or ($7.26) on an earnings per share basis.

How many employees does Novavax have?

The company employs 1,992 workers across the globe.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.

This page (NASDAQ:NVAX) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -